StockTipsArenaBeta

BUY Concord Biotech Limited — Sachin Janardan Sarvade, IDBI Capital Markets and Securities

BUYConcord Biotech Limited
Concord Biotech share price target & all analyst calls

bySachin Janardan Sarvade, IDBI Capital Markets and SecuritiesHorizon: Swing (≤2wk)15 Sept 2026via NDTV Profit (Live)

Entry₹1,513.6Inferred
Target₹1,717
Total upside +13.44% (call closed)
Stop loss₹1,399-7.57% risk
Exit₹1,39928 Sept 2026, 3:00 pm
Stop-loss hit-7.57%
Follow Sachin Janardan Sarvade for new calls(16% target hit, 87 closed calls)Get alertsWatch CONCORDBIO for new buy/sell callsGet alertsSee 1 active Swing call on CONCORDBIOSee 236 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 28 Sept 2026
6 supporting0 opposing
Supports the BUY call (6)

Concord Biotech announces 1:1 bonus share issue; shareholders to get one free share for each held

NewsCnbc-Tv18·23 Sept · 4d ago

(opens in new tab)

Concord Biotech 1:1 bonus issue: Jhunjhunwala family-backed pharma stock gains 50% in 6 months, check record date detail

NewsLivemint·23 Sept · 4d ago

(opens in new tab)

Concord Biotech Ltd's Board approved the issuance of Bonus shares and an increase in Authorised Share Capital during their meeting on September 23, 2026.

BSE · Board Meeting·23 Sept · 4d ago

(opens in new tab)

Concord Biotech bonus issue sparks rally! Pharma stock jumps 6% on maiden share reward - Top things to know

NewsLivemint·21 Sept · 6d ago

(opens in new tab)

Bonus Alert: Stock with significant Jhunjhunwala family stake set to reward shareholders

NewsCnbc-Tv18·21 Sept · 1w ago

(opens in new tab)
Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Concord Biotech

All analyst calls on Concord Biotech

More from Sachin Janardan Sarvade, IDBI Capital Markets and Securities

Every call and its outcome